CD274 and neoplasm: Second, cost-effectiveness is likely to vary by country, tumor histology, PD-L1 expression, and competing domestic pricing/reimbursement frameworks; therefore, region-specific economic evaluations are urgently needed to inform reimbursement and guideline decisions (63).